Clavis and Clovis Sign Licensing Deal for Cancer Drug
Start-up biotech Clovis Oncology has signed a $380 million deal to license an experimental pancreatic cancer drug from Norwegian company Clavis Pharma.
ganymed pharmaceuticals
Melanoma Drug Called a “Breakthrough” After Study
Scientists are calling Plexxikon’s experimental skin cancer drug a “breakthrough” after it successfully shrank tumors in clinical trial patients.